RecruitingPhase 4NCT06578520

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Effect of the Use of Dapagliflozin in Diuresis, Natriuresis and in Ultrafiltration and Peritoneal Elimination of Sodium, in Patients With Refractory Heart Failure

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Enrollment

31 participants

Start Date

Jul 30, 2024

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether dapagliflozin — a medication commonly used for diabetes and heart failure — can help people with refractory heart failure (heart failure that has not responded well to standard treatments), to improve symptoms and outcomes. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of heart failure according to clinical guidelines (NYHA functional classification) - Your heart failure has not responded adequately to standard treatments - You are able to provide informed consent **You may NOT be eligible if...** - You have type 1 diabetes - You have severe kidney impairment - You have had a recent serious cardiac event - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.